Display options
Cite
Davis CT, Rizzieri D. Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel). 2015;8(2):250-6doi: 10.3390/ph8020250.
Davis, C. T., & Rizzieri, D. (2015). Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel, Switzerland), 8(2), 250-6. https://doi.org/10.3390/ph8020250
Davis, Carter T, and Rizzieri, David. "Immunotherapeutic applications of NK cells." Pharmaceuticals (Basel, Switzerland) vol. 8,2 (2015): 250-6. doi: https://doi.org/10.3390/ph8020250
Davis CT, Rizzieri D. Immunotherapeutic applications of NK cells. Pharmaceuticals (Basel). 2015 May 25;8(2):250-6. doi: 10.3390/ph8020250. PMID: 26020141; PMCID: PMC4491659.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2015 May 25;8(2):250-6. doi: 10.3390/ph8020250.

Immunotherapeutic applications of NK cells.

Pharmaceuticals (Basel, Switzerland)

Carter T Davis, David Rizzieri

PMID: 26020141 PMCID: PMC4491659 DOI: 10.3390/ph8020250

Abstract

Natural Killer (NK) cells are lymphoid cells that exhibit an innate response against virus-infected cells. These cells are also capable of mounting an immune response against tumor cells after education through major histocompatibility complex (MHC) class I molecules. NK cell regulation is mediated through IFN-gamma and IL-15, important cytokines which can drive NK cell expansion in vivo. Previous studies have shown effective infusion of allogeneic NK cells after lymphodepleting regimens with induction of remission of poor prognosis acute myeloid leukemia (AML). Challenges remain in the expansion of these NK cells once infused and in their education to recognize tumor targets. A principal mechanism of tumor recognition is through KIR mismatch in cells lacking self MHC I molecules. Activating KIRs exist, though their ligands are unknown at this time. Impacting NK cell expansion and education in vivo has been challenging, and thus far clinical applications of NK cells have shown promise in helping to maintain remission in humans, though this remission has not been maintained. Future efforts to utilize NK cells clinically are focusing on developing more consistency in successful expansion of NK cell and educating them to recognize their tumor targets. Additional efforts to utilize novel antibody-based therapy to engage NK cells to their tumor targets are also in development.

Keywords: Natural Killer cells; cellular therapy; hematopoietic stem cell transplant; leukemia

References

  1. Immunity. 1997 Dec;7(6):753-63 - PubMed
  2. Cell. 1995 Sep 8;82(5):697-700 - PubMed
  3. Immunol Rev. 1997 Feb;155:183-96 - PubMed
  4. Cytotherapy. 2009;11(3):341-55 - PubMed
  5. Blood. 2011 Jan 20;117(3):1021-9 - PubMed
  6. PLoS One. 2011;6(6):e20740 - PubMed
  7. Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14 - PubMed
  8. Exp Hematol. 2001 Oct;29(10):1157-68 - PubMed
  9. Int Immunol. 2001 Apr;13(4):459-63 - PubMed
  10. Annu Rev Immunol. 2011;29:235-71 - PubMed
  11. PLoS One. 2010 Feb 15;5(2):e9221 - PubMed
  12. Front Immunol. 2014 Mar 17;5:95 - PubMed
  13. Blood. 2009 Jan 15;113(3):726-32 - PubMed
  14. Nat Rev Immunol. 2012 Mar 22;12(4):239-52 - PubMed
  15. Hematology Am Soc Hematol Educ Program. 2013;2013:247-53 - PubMed
  16. PLoS One. 2012;7(1):e30264 - PubMed
  17. Blood. 2005 Apr 15;105(8):3051-7 - PubMed
  18. Science. 2002 Mar 15;295(5562):2097-100 - PubMed
  19. Blood. 2009 Jun 18;113(25):6382-5 - PubMed
  20. Immunol Today. 1990 Jul;11(7):237-44 - PubMed
  21. Trends Immunol. 2001 Nov;22(11):633-40 - PubMed
  22. J Immunol. 2009 Nov 15;183(10):6579-87 - PubMed
  23. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9 - PubMed
  24. Mol Immunol. 2002 Feb;38(9):637-60 - PubMed
  25. Nature. 2001 Apr 26;410(6832):1107-11 - PubMed
  26. Springer Semin Immunopathol. 2005 Jun;27(1):49-64 - PubMed
  27. Immunity. 2008 Apr;28(4):571-80 - PubMed
  28. Annu Rev Immunol. 2002;20:217-51 - PubMed

Publication Types